ABSTRACT
INTRODUCTION
Ischemia/reperfusion injury (IRI) accounts in large measure for early dysfunction or non-function of transplanted organs and is thought to contribute to the acute and/or chronic events that can lead to graft rejection. The pathogenesis of IRI involves primarily components of the host innate immune system such as activation of the complement cascade as well as neutrophil and monocytemacrophage activation (1, 2) . A number of putative factors in the graft itself have been implicated in the pathogenesis of IRI. These include alteration of calcium concentration, ATP depletion and free radical mediated cell damage (3) . In the case of transplanted livers, IRI can result in very significant levels of apoptosis, which presumably contributes to or accounts for primary graft nonfunction associated with prolonged IRI (2) . We have recently demonstrated that over-expression of the stress responsive gene heme oxygenase-1 (HO-1) exerts potent cytoprotective effects in experimental models of hepatic (4), cardiac (5) and renal (6) IRI in rats. However, the putative mechanisms by which HO-1 leads to cytoprotection during IRI remain unclear.
Heme oxygenases (HOs) are ubiquitous enzymes that catalyze the initial and rate-limiting steps in the oxidative degradation of heme to bilirubin (7). HOs cleave a mesocarbon of the heme molecule, producing equimolar quantities of biliverdin, iron, and carbon monoxide (CO).
Biliverdin is reduced to bilirubin, by bilirubin reductase, and the free iron released from heme is used in intracellular metabolism and induces the expression of the iron chelator ferritin, by which it is sequestered (8). Three HO isoforms have been identified: HO-1 (an inducible heat shock protein, i.e. hsp32), HO-2, (a constitutive form expressed primarily in brain and testis), and a less well-characterized HO-3. HO-1 is the only inducible form of the HOs and confers potent cytoprotective effects in the context of organ transplantation (reviewed in (9)). At a cellular level the mechanism(s) by which HO-1 confers cytoprotection against oxidative stress was linked initially to its ability to induce the expression of ferritin (10).
Ferritin is a ubiquitous protein forming a shell consisting of 24 symmetrically related subunits. Two different subunits are known: a heavy (H) and a light (L) chain. Ferritin has a high capacity to store free iron by oxidizing Fe 2+ to Fe
3+
, and thus acts as an effective anti-oxidant molecule by reducing the availability of intracellular free Fe 2+ that can participate in the generation of free radicals through the Fenton reaction (11). This property of ferritin is attributed primarily to the heavy chain subunit (H-ferritin), the only one that has ferroxidase activity (12).
Expression of HO-1 is associated with up-regulation of H-ferritin, which is thought to contribute to the ability of HO-1 to protect endothelial cells (EC) from the cytotoxic effects of activated neutrophils and H 2 O 2 (10) as well as from oxidized low-density lipoproteins (13). Other molecules that chelate free iron (e.g., deferoxamine mesylate) have also been shown to prevent EC from undergoing apoptosis (14), suggesting that H-ferritin may have similar effects.
In the present study we tested a hypothesis that expression of H-ferritin contributes in a critical manner to the effect of HO-1 in terms of protecting cells from apoptosis and transplanted organs from IRI. We have obtained several independent lines of evidence suggesting that this indeed is the case.
METHODS

Animals. Inbred male Sprague Dawley (SD) rats weighing 200 to 250 g (Harlan Sprague
Dawley, Indianapolis, IN) were used throughout this study. (Sigma Chemical CO) was dissolved in water and added to culture medium (1-100 µM). Iron protoporphyrin (FePP/heme) and tin protoporphyrin (SnPPIX) (Porphyrin Products Inc., Logan, UT) were dissolved (10 mM) in 100 mM NaOH and stored at -20 o C until used.
Metalloporphyrins were added to the culture medium (50 µM), 6 hours after transfection. Human recombinant TNF-α (R&D, Systems, Minneapolis, MN) was dissolved in PBS, 0.1% bovine serum albumin and added to the culture medium (10-100 ng/ml), 24 hours after transfection.
CO exposure. Cells were exposed to varying concentration of CO (250 and 10,000 ppm), as described elsewhere (14).
Expression plasmids. β-galactosidase cDNA (Clontech Laboratories, Palo Alto, CA) was cloned into the pcDNA3 vector (Invitrogen, Carlsbad, CA), as described before (15 pH (7.3-7.4). Portal venous blood flow, bile production, and serum AST and ALT levels were assessed serially according to a previously described method (4) . At the conclusion of experiment, liver samples were collected for histological evaluation and myeloperoxidase (MPO) activity according to a previously described method (26).
Rat orthotopic liver transplantation. Donor SD rats were either untreated, pretreated with HFerritin or β-galactosidase adenoviruses (2.5x10 9 pfu iv). Livers were harvested 48h later, stored for 24 h at 4 0 C in UW solution, and grafted orthotopically into SD rat recipients (n=6 rats/group). Orthotopic liver grafting was carried out by utilizing Kamada's method with modifications (27). Liver recipients were monitored daily up to 2 weeks post-transplantation, and their survival was assessed.
Histology. Liver samples were fixed in 10% buffered formalin, embedded in paraffin, sectioned, and stained with Hematoxylin and Eosin. The Suzuki's criteria were used to evaluate the histologic severity of hepatic IRI (28). In this classification, sinusoidal congestion, hepatocyte necrosis and ballooning degeneration are graded from 0 to 4. No necrosis, congestion or centrilobular ballooning is given a score of 0, while severe congestion and ballooning degeneration as well as > 60% lobular necrosis is given a value of 4 (28).
Detection of apoptosis. Liver specimens were processed for immunostaining using terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) technique, as described (29). Accumulated internucleosomal DNA fragments (apoptosis) were detected serially on cardiac sections (4 µm in thickness) using an TACS 2 TdT in situ apoptosis detection kit (Trevigen TM , Inc. Gaithersburg, MD).
Cell extracts and Western blot analysis. Cell extracts were prepared, electrophoresed under denaturing conditions (10-12.5% polyacrylamide gels) and transferred on polyvinyldifluoridine (PVDF) membranes (Immobilon P, Millipore, Bedford, MA), as described elsewhere (14). HO-1 was detected using a rabbit anti-human HO-1 polyclonal antibody (StressGen, Biotechnologies
Corp., Victoria, CA). H-ferritin was detected using a rabbit anti-human ferritin polyclonal antibody (Dako Corp., Carpinteria, CA). β-tubulin was detected using a murine anti-human The amount of H-ferritin expression was quantified using ImageQuant software (Molecular Dynamics, Sunny Vale, CA).
Statistical analysis.
All results were calculated as the mean ± standard deviation (mean ± SD).
The unpaired student's t-test was applied to analyze differences between the groups. For the comparison of the graft survival, the Mann-Whitney U test was used. All differences were considered statistically significant at the p-value of <0.05.
RESULTS
H-Ferritin is a product of endogenous heme catabolism by HO-1.
We have confirmed that up-regulation of endogenous HO-1 in EC by iron protoporphyrin (Hemin/FePP) is associated with a concomitant up-regulation of ferritin expression ( ( Fig. 2C ). Therefore all subsequent experiments were carried out using H-ferritin in the protective range (1-100 ng per 3 x 10 5 cells); i.e. at doses lower than any noted to cause toxicity.
In the absence of HO-1 activity H-Ferritin protects EC from undergoing apoptosis.
Blocking HO-1 activity with SnPPIX suppressed HO-1-derived ferritin expression (data not shown). The absence of H-ferritin under such conditions also led to the loss of the protective effect of HO-1 (Fig. 3A) . In contrast, SnPPIX did not impair the anti-apoptotic effect of Hferritin expression secondary to transient transfection ( Fig. 3A) or exogenously administered CO (10,000 ppm) (Fig. 3B ).
H-Ferritin and CO have additive protective activity in EC.
As shown above, H-ferritin makes a significant contribution to the anti-apoptotic function of HO-1. We have previously shown that CO also has anti-apoptotic properties (14, 30). Therefore we asked whether these two products of HO-1 activity would complement each other in their protective function. EC were transfected with various amounts of H-ferritin ranging from suboptimal (0.1ng per 3 x 10 5 cells) to optimal (1ng per 3 x 10 5 cells) doses. Cells were separately exposed to low level of exogenous CO (250 ppm), which protects EC from apoptosis to only a minor extent (30-40% apoptotic cells) (Fig. 4) . The combination of exogenous CO plus low dose H-ferritin expression protected EC to almost 100%, even though each component was used at a sub-optimal dose (Fig. 4) . This is especially apparent at 0.1 ng/ per 3 x 10 5 cells of pcDNA3/Hferritin (which alone showed no significant protective effect) plus CO, with the combination showing protection significantly above CO alone.
Recombinant adenovirus mediated H-ferritin expression protects livers from ex-vivo reperfusion injury.
Rat livers exposed to prolonged cold ischemia (UW solution, 4 o C, 24h) showed severe signs of injury once re-perfused ex-vivo with whole syngeneic blood (4). Liver injury was evidenced by the relative low increase in portal blood flow (from 0.63 ± 0.076 ml/min/g at time 0 to 1.13±0.23
at ml/min/g at 120 min) (Fig. 5A ) and bile production (from 0.00338±0.0078 ml/g at time 0 to 0.025±0.01 ml/g at 120 min) (Fig. 5B ) following reperfusion as well as by a significant increase in ALT release (from 7.2 ± 4.9 IU/l at time 0 to 173±71 IU/l at 120 min)( Livers transduced with the H-ferritin gene also had a significantly better preservation of their histological detail, as compared to non-transduced (p<0.05) or β-galactosidase (p<0.05) transduced livers, as assessed by standard Suzuki's pathological scoring (Fig. 6 ). H-ferritin transduced livers had relatively lower levels of congestion, centrilobular ballooning, and necrosis as compared to non-tranduced or β-galactosidase transduced livers (Fig. 6) .
Recombinant adenovirus mediated H-ferritin expression prevents IRI following orthotopic liver transplantation.
Livers from SD rats exposed to prolonged cold ischemia (U.W. solution, 4 o C, 24 hours)
showed severe signs of hepatocellular damage following transplantation into syngeneic SD recipients (Fig. 7) . This was evidenced by the high serum levels of AST 24 hours post-transplant (3928±1455 IU/L) (Fig. 7) . Similar results were obtained in liver transplant recipients transduced with a β-galactosidase recombinant adenovirus (4887±500 IU/L) (Fig. 7) . In marked contrast, in animals bearing liver transplants transduced with the H-ferritin recombinant adenovirus AST release (1368±550.8 IU/L) was significantly inhibited as compared to β-galactosidase/untreated groups (p< 0.05) (Fig. 7) .
That H-ferritin transduced livers were protected from IRI is strongly supported by the demonstration that up to 90% of livers transduced with H-ferritin survived long-term (>14days) when transplanted into syngenic SD recipients. In marked contrast, only 40-50% of nontransduced or β-galactosidase transduced livers survived >14 days when transplanted into syngenic SD recipients (Fig. 8) . The relative number of cells undergoing apoptosis in H-ferritin transduced livers transplanted into syngeneic recipients was significantly reduced as compared to non-transduced or β-galactosidase transduced livers transplanted under the same conditions ( . In different cell types, over-expression of ferritin protects from stimuli such as H 2 O 2 (10) ultraviolet irradiation and oxidized low-density lipoproteins (13).
The mechanism underlying the protective effect of ferritin is not clear. We demonstrate
here that H-ferritin protects EC from undergoing apoptosis (Fig. 2) . This protective effect is dose-dependent and is observed for several pro-apoptotic agonists such as TNF-α, etoposide and serum deprivation (Fig. 2) . We have tested specifically the anti-apoptotic action of the H-chain of ferritin, as only the H-chain manifests ferroxidase activity and the L-chain is not able to counteract iron oxidation (12, 36). By suppressing endogenous HO-1 activity with SnPPIX, we showed that the anti-apoptotic effect of H-ferritin does not require endogenous HO-1 activity (Fig. 3) .
Similarly to HO-1(37), H-ferritin shows toxic effects at high concentrations (Fig. 2 ). This is consistent with studies showing the potential pro-oxidant nature of ferritin caused by released reactive iron (38, 39). However, our data suggest that H-ferritin has protective effects in a very wide range (approximately 100 fold) before becoming toxic whereas HO-1 has a much narrower therapeutic range (approximately four-fold, data not shown).
At low doses, at which H-ferritin showed no significant anti-apoptotic effect and CO only a minor one, the combination of the two protected EC to nearly 100% (Fig. 4) . This suggests that these two end products of HO-1 action on heme can act together in an additive, perhaps synergistic manner. Given that HO-1 and ferritin are toxic at high levels, and given the known harmful effects of CO at high concentrations (formation of carboxyhemoglobin and inhibition of mitochondrial respiration), the use of these two molecules, at low non-toxic doses, might be better for in vivo therapeutic applications.
Based on these findings we asked whether the anti-apoptotic action of H-ferritin could be used in a therapeutic manner to prevent the deleterious effects resulting from acute inflammatory conditions. We have tested this hypothesis in an experimental model of liver IRI because of the key role of apoptosis in this type of injury. We found that in recombinant H-ferritin adenovirus transduced livers exposed to prolonged cold ischemia there was a significant protection from injury caused by ex-vivo reperfusion with whole blood, as compared to non-transduced or β-galactosidase recombinant adenovirus transduced livers (Fig. 5) . This notion is supported by the observation that H-ferritin transduced livers had higher levels of portal blood flow and bile production (two markers of liver function in this experimental system), as compared to non-transduced or β-galactosidase transduced livers (Fig. 5) . In addition, H-ferritin transduced livers also had significant lower levels of ALT release (a marker of hepatocellular injury) and MPO accumulation (a marker of neutrophil activity) as well as a significantly better preservation of morphological structure as compared to non-transduced or β-galactosidase transduced livers ( Fig. 5 and 6 ).
We found that the protection of livers from IRI, conferred by the expression of the H-ferritin gene, was still observed upon liver transplantation (Fig. 7, 8 and 9) . Indeed, the survival rate of syngeneic recipients transplanted with H-ferritin transduced livers was 90%
while that of syngeneic recipients transplanted with non-transduced or β-galactosidase transduced livers was only 40-50% (Fig. 8) . The higher rate of survival in recipients transplanted with H-ferritin transduced livers was consistent with the significantly improved hepatocyte function ( Fig. 7) as well by a lower relative number of cells undergoing apoptosis ( If there were no additional effects of H-ferritin beside its ability to modulate NF-κB activation, then H-ferritin would sensitize liver heptocytes to TNF-α mediated apoptosis, since NF-κB activation is required for the expression of anti-apoptotic genes that protect these cells from TNF-α mediated apoptosis (45) . Based on this reasoning, we hypothesized that H-ferritin expression in the liver must have an anti-apoptotic effect as well. Our data supports this hypothesis, both in vitro (Fig. 2 ) and in vivo (Fig. 9) . Presumably this anti-apoptotic effect of Hferritin contributes to the overall protection of livers against IRI, consistent with our most recent data using IDN-6556, an irreversible caspase-3 inhibitor which also protects livers from IRI in the same experimental model (unpublished observation).
In conclusion, our present studies provide evidence that H-ferritin has a potent antiapoptotic function. In addition, we show that H-ferritin can be used therapeutically to protect livers from IRI. When indicated livers were transduced with β-galactosidase or H-ferritin adenoviruses, as described in Methods. Different liver parameters that correlate with liver metabolic function and cytotoxicity were analyzed in a ex-vivo reperfusion system using whole syngenic blood, as 
